REGN Regeneron Pharmaceuticals, Inc. | US75886F1075
Financials
Trends
Details
| Breakdown | 31.12.2027 | 31.12.2026 | Change % |
|---|---|---|---|
| Total Revenue | 17.607.941.730 | 15.872.613.230 | 10.93% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| Operating Expense | -- | -- | -- |
| Selling General and Administrative | -- | -- | -- |
| Research & Development | -- | -- | -- |
| Operating Income | -- | -- | -- |
| Pretax Income | -- | -- | -- |
| Net Income Common Stockholders | -- | -- | -- |
| Basic EPS | 47,40 | 45,85 | 3.38% |
| Diluted EPS | -- | -- | -- |
| Analyst Count | 9 | 27 | 66.67% |
| EBIT | -- | -- | -- |
| EBITDA | -- | -- | -- |